RADO
Asset Logo

Radiopharm Theranostics Limited

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Radiopharm Theranostics Limited - Option Expiring 30-Nov-2026

πŸ“ˆ Performance

Price History

N/A

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in RADO

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in RADO

N/A
RADO investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in RADO also invest in...

Want more shares? Try these...

Radiopharm Theranostics Limited

RADOA

πŸ“Š Share price

$0.01 AUD
Find Out More

Ragnar Metals Ltd. engages in the business of exploring and evaluating nickel, gold, silver, and base metals projects in Scandinavia and Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-03-31. The firm is engaged in the exploration and evaluation of its projects in Scandinavia and commencement of the exploration and evaluation of its Australian projects. Its projects consist of Halleberget Lithium Project, Bergom Lithium Project, Orrvik Lithium Project, Leeds Project, and Kenya Project. The Halleberget Project is located 10 km along strike to the north of Sweden's lithium pegmatite resource at Jarkvissle. The Bergom project is located 100 km east-northeast of Halleberget and is in an area of known LCT pegmatites. Oslerum North HREE Project tenure comprises 20.8 square kilometer (km2), located 8.5 km north of the Olserum HREE deposit. Gruvhagen REE (NdPr) Project tenure comprises 16.5 km2 tenure, located 20 km north of Ragnar Metals Granmuren nickel (Ni)-copper (Cu) discovery. The Orrvik Lithium Project comprises of 36 km2 of highly prospective tenure.

πŸ™Œ Performance (5Yr p.a)

40.00%

πŸ“Š Share price

$0.02 AUD

πŸ“ˆ HIGH PRICE GROWTH

⛏️ MINING

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

πŸ™Œ Performance (5Yr p.a)

244.17%

πŸ“Š Share price

$1.58 AUD

🧬 BIOTECHNOLOGY

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The company has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

πŸ“Š Share price

$0.02 AUD

🧬 BIOTECHNOLOGY

Compare
Add to watchlist